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The platelet-activating factor (PAF) represents a phospholipid with complex biological functions, including in-
volvement in inflammatory processes. The degrading enzyme PAF acetylhydrolase (PAFAH) represents a candidate
for asthma and other atopic diseases. Two loss-of-function mutations of PAFAH are associated with severe asthma
in Japanese individuals. Our aim was to look for further PAFAH variants in white populations, their possible
association with atopic and asthmatic phenotypes, and their functional importance. We picked up three common
variants in the PAFAH gene: Arg92His (exon 4), Ile198Thr (exon 7), and Ala379Val (exon 11). The known loss-
of-function mutations were not seen. The variant allele Thr198 was found to be highly associated with total IgE
concentrations in an atopic population ( ) and with “atopic asthma” in an asthmatic population (P = .009 P =
). The variant allele Val379 was found to be highly associated with “specific sensitization” in the atopic.008
population ( ) and with “asthma” in the asthmatic population ( ). By use of recombinant PAFAHP = .002 P = .003
enzymes, the variant Val379 showed increased (14 mM) and Thr198 markedly increased (42 mM) KM values
compared to the wild type (7 mM); furthermore, Vmax of Val379 was highly increased (132%). Thr198 and Val379
influence plasmatic PAFAH toward lower substrate affinities and therefore are very likely to prolong the activities
of PAF. At the same time, they are associated with an increased risk to develop asthma and atopy. Thus, two
PAFAH variants seem to play a key role in atopic and asthmatic processes in Caucasian populations.
Introduction
The platelet-activating factor (PAF) represents a phos-
pholipid with a variety of biological functions. Beside
others, it is involved in the signaling and activation of
proinflammatory cells such as platelets, neutrophils, and
macrophages (Prescott et al. 1990) and also was shown
to inhibit apoptosis of B cells (Toledano et al. 1999).
Furthermore, it has been reported to alter vascular per-
meability and to induce hypertension, platelet-dependent
bronchoconstriction, and smooth-muscle contraction
(MIM 145500; MIM 208550) (Miwa et al. 1988).
Therefore, PAF is involved in and associated with many
inflammatory diseases including the allergic disorders
(MIM 147050) (Averill et al. 1992). An increase in PAF
levels has been shown during acute asthmatic attacks in
children (Hsieh and Ng 1993).
The release and degradation of PAF is controlled by
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intracellular and plasmatic PAF-acetylhydrolases (PA-
FAH). PAFAH represent functional antagonists of PAF,
and the coding genes count as important candidate
genes for atopic diseases (MIM 147050) (Tjoelker et al.
1995a). The gene for the plasmatic PAFAH has been
mapped to chromosome 6p21.2-p12 (Stafforini et al.
1996), originally assigned as the human leukocyte an-
tigen region. Previously, linkage was found in this region
between microsatellite markers and asthma and atopy
phenotypes (Ober et al. 1998; Wjst et al. 1999). An
acquired deficiency of plasmatic PAFAH (PAFAH) has
been shown in patients with systemic lupus erythema-
tosus (MIM 152700) and bronchial asthma (MIM
208550) (Tetta et al. 1990; Tsukioka et al. 1993). In
addition, two common loss-of-function mutations in the
plasmatic PAFAH gene (situated in exon 9) have been
shown to be associated with severe asthma and stroke
(Val279Phe [MIM 601367]) and various cardiovascular
diseases (Gln281Arg [MIM 208060; MIM 600995])
(Hiramoto et al. 1997; Yamada and Yokota 1997; Ya-
mada et al. 1998; Satoh et al. 1999; Stafforini et al.
1999a). To date, however, these loss-of-function mu-
tations were found only in Japanese populations, not
in white ones. Two further gene variants, Ile198Thr
(exon 7) and Ala379Val (exon 11), have been described
in the context of schizophrenia (MIM 181500) (Bell et
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al. 1997). Our interest was to investigate whether any
variant of the PAFAH gene found in white populations
would be associated with atopy or asthma and would
impair the enzymatic activity.
Material and Methods
Screening Population (German)
The screening for mutations was performed in a sep-
arate population of 50 unrelated individuals recruited
randomly without regard to an atopic history. These
were not included in any of the following statistical
evaluations.
Atopic Population (German)
Individuals were recruited in the southwestern part of
Germany as described elsewhere (Kruse et al. 1999). An
atopic child served as the index patient.
The genotyping and association studies were per-
formed in 260 atopic and nonatopic children (first-de-
gree siblings from 105 families) ranging in age from 6
to 22 years (mean 15 years) who were recruited through
two studies (Kruse et al. 1999). Of these children, 77%
(199 individuals) were atopic according to the definition
stated below, whereas 63% (162 individuals) showed
total IgE concentrations 1100 kU/liter, 73% (189 indi-
viduals) showed specific sensitization to common inha-
lant allergens, and 11% (29 individuals) were asthmat-
ics. Of the families, 45% presented with at least one
unaffected child. The determinations of allele frequen-
cies, linkage disequilibrium, and estimates of Hardy-
Weinberg equilibrium were performed in the 105 un-
related eldest children of the families.
Specific IgE was detected by enzyme-linked immu-
nosorbent assays against two mixtures of grass pollens,
Dermatophagoides pteronyssinus, Dermatophagoides
farinae, cat dander, and birch pollens (Magic Lite, Chi-
ron Diagnostics). The cut-off point for a positive test
was 1.43 Magic Lite units (Kleine-Tebbe et al. 1992).
Detectable IgE to at least one of the four allergens or a
positive skin-prick test response to one of the same al-
lergens was the criteria for “any specific sensitization.”
Measurement of total serum IgE was carried out by an
enzyme allergosorbent test (Phadezym, Pharmacia).
“Atopy” was defined by at least one positive specific IgE
test or by an elevated total IgE concentration 1100 kU/
liter (Kjellman et al. 1976).
Approval
The collection of serum and DNA material, as well
as the experiments, have been approved by the Ethical
Commission of the University of Freiburg (June 12,
1994, and August 10, 1996).
Asthmatic Population (British)
Details of the selection of the case-control studies for
the British population (300 unrelated individuals) were
described elsewhere (Gao et al. 1998). With atopy de-
fined as for the atopic population (see above), 150 in-
dividuals showed “atopic asthma,” 31 were asthmatic
without atopic traits, and 119 served as nonasthmatic
controls (Gao et al. 1998). The phenotype “asthma”
comprises a combination of all asthmatics (181 individ-
uals). Hardy-Weinberg estimates and the determination
of allele frequencies were performed separately from the
atopic population.
All the asthmatic subjects had specialist physician–
diagnosed asthma with (1) recurrent breathlessness and
chest tightness requiring ongoing treatment, (2) physi-
cian-documented wheeze, and (3) documented labile air-
flow obstruction with variability in serial peak expira-
tory flow rates 130%. There were no heavy smokers
(1350 pack per year) among the subjects. The phenotype
“asthma” consisted of atopic and nonatopic asthmatic
patients.
Amplification of Genomic DNA by PCR
DNA was extracted from peripheral blood leukocytes,
following standard protocols, and was column purified
(DNA midi kit, Qiagen; IsoQuick, Microprobe). We
screened for polymorphisms in the entire gene of plas-
matic PAFAH (Stafforini et al. 1996), using the appro-
priate primers to gain ∼300-bp fragments (not all prim-
ers listed). To amplify the target DNA in the poly-
morphic regions we used five oligonucleotide primer
pairs: exon 2, 5′- TTTCTTGATTTGTCAGCTTA-3′ and
5′-CAACTTCTTGGGGCCCACTTG-3′; exon 4, 5′-CG-
AAAATAGCTGCTGGAATA-3′ and 5′-AGTTCTTGT-
TGTTTTCAAGG-3′; exon 7, 5′-ATAAATAATTTTGC-
TTGTAT-3′ and 5′-TAGGAGCATAACTTGCCAGG-3′;
exon 9, 5′-CTATAAATTTATATCATGCT-3′ and 5′-TT-
TACTATTCTCTTGCTTTAC-3′; and exon 11, 5′-TTT-
TAAATGTCTTGTTCTCT-3′ and 5′-GGTCATGAAA-
AAAATAGTTT-3′. PCR was carried out in a volume of
10 ml containing 30 ng DNA, 5 pmol of each primer,
0.06 U Taq polymerase (Pharmacia), and 2 mmol dNTP
mix with the buffer recommended by the supplier. After
denaturation for 5 min at 947C, 35 cycles were carried
out, each cycle consisting of 45 s at 947C, 90 s at 537C
(exon 2 and exon 11)/ 557C (exon 4 and exon 7)/ 507C
(exon 9) and 90 s at 727C. The last synthesis step was
extended to 10 min.
Sequencing
Sequencing by the dideoxy chain termination method
was performed on an automated sequencer (ALF DNA
Analysis System, Pharmacia).
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SSCP Analysis
For SSCP analysis (Orita et al. 1989), the amplified
products were resolved on nondenaturing 10% or 12%
polyacrylamide gels containing 10% glycerol at 207C
for 2 h. The gels were silver-stained as described else-
where (Hiort et al. 1994). Sequencing was performed
for all observed SSCP variants.
Restriction Fragment–Length Polymorphism Analysis
PCR for genotyping was performed with mutated
primers introducing a restriction site for RFLP analysis
in dependence on the respective genotype: Arg92His,
5 ′ -CGAAAATAGCTGCTGGAATA-3 ′ and 5 ′ -
AGTTCTTGTTGTTTTCAAGG-3 ′ ; BclI-RFLP.
Ile198Thr: 5′-ATAAATAATTTTGCTTGTAT-3′ and
5′-AGAGCCAAGACTTGTCAGCT-3′; PvuII-RFLP.
Ala379Val: 5′-GGGAGACATAGATTCAACTG-3′ and
5′-GGTCATGAAAAAAATAGTTT-3′; PstI-RFLP (all
from NEB). Restriction was performed in a volume of
10 ml containing 5 ml of the PCR-product and the buffer
recommended by the supplier for 90 min at 377C. The
fragments were resolved on 12% polyacrylamide gels.
Two known homozygote individuals and one hetero-
zygote individual, as confirmed by sequencing, were in-
cluded in each reaction. The genotyping was performed
by two investigators who were unaware of the
phenotypes.
Statistical Analysis
Atopic population.—The number of alleles for each
polymorphism was counted in all 260 children of the
study populations, as far as the genotype could be de-
termined unequivocally (that is, in 98% of the individ-
uals). To account for the individuals who were siblings
and to adjust for age and sex of the study population,
regression analysis has been applied. We performed
logistic regression analysis and linear regression analy-
sis for the explanation of the phenotypes “asthma,”
“atopy,” and “specific sensitization to common inhalant
allergens,” treated as a dichotomic parameter, and “total
serum IgE,” treated as a continuous parameter on a log-
arithmic scale by the genotypes “presence of the poly-
morphic allele.” Analysis followed the method of Zeger
and Liang (1986) to account for the correlation between
sibs. The average IgE concentration in individuals bear-
ing one of the polymorphisms is calculated by 10 to the
estimate. A P value of .009 was considered significant,
to account for multiple testing.
Asthmatic population.—Contingency-table analysis,
odds ratios, 95% confidence intervals, and significance
values were estimated by computerized methods (SPSS,
version 8). For both populations, the probability values
were corrected for multiple comparison by multiplying
the P values by number of loci compared (Bonferroni
correction).
Linkage Disequilibrium
The linkage disequilibrium (D) was calculated sepa-
rately in the atopic and asthmatic population according
to the method of Mittal (1976). A t value calculated by
D/standard error (SE) 11.96 was considered positive.
Haplotype frequencies were estimated using the program
TRANSMIT, version 2.5 (Clayton 1999; Clayton and
Jones 1999).
Preparation of cDNA
mRNA was isolated from human whole blood by use
of the RNeasy blood mini kit (Qiagen). The cDNA was
synthesized by the “first-strand cDNA synthesis kit“
(Amersham/Pharmacia).
Functional Studies
Wild-type cDNA, coding for the mature protein, was
amplified by PCR with primers introducing a KpnI
(Pharmacia) restriction site at the 5′ and 3′ ends of the
coding gene (primers 5′-GCGCGGTACCATACAAGT-
ACTGATGGCTGC-3′ and 5′-GCGCGGTACCCTAAT-
TGTATTTCTCTATTCC-3′). The fragment was cloned
into a bacterial expression vector (pQE; Qiagen) and
transformed into Escherichia coli (E. coli) BL21DE3
pLysS. Positive clones were confirmed by sequencing and
by expression analysis according to the supplier’s pro-
tocols. In the system used, six histidine residues are
added to the protein at the N-terminus in order to
facilitate purification by affinity-chromatography (Ni-
NTA resin, Qiagen).
PCR and primers bearing the polymorphic base pairs
were used to produce a total of nine different mutant
enzymes: wild type; His92 (PAF4); Thr198 (PAF7);
Val379 (PAF11); PAF 4/7; PAF 4/11; PAF 7/11; PAF 4/
7/11. The loss-of-function mutation Phe279 served as
a control. The mutant constructs were confirmed by
sequencing.
Kinetic Studies
Enzyme characterizations were performed with equal
amounts of purified proteins (according to BioRad Pro-
tein assay, BioRad), using the standard enzymatic test
(substrate: acetyl-3H-PAF) and recommended reagents
(Stafforini et al. 1990). KM and Vmax were measured
in three parallel reactions with increasing substrate con-
centrations (1/10/50/100 mM), and mean values were
calculated. Data was fitted to the Michaelis-Menten
equation by nonlinear regression with the program Enz-
fitter (Biosoft). For substrate inhibition assays we used
substrate concentrations of 0.1–1 mM. The results of all
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Table 1
Allele Frequencies of Common Polymorphisms in Human Plasmatic PAFAH
POLYMORPHISM
FREQUENCY IN POPULATION (%)
Atopic (German) Asthmatic (British)
Nonatopic (n = 33) Atopic (n = 72) Nonatopic (n = 150) Atopic (n = 150)
His92 24.1 25.4 23.2 23.4
Thr198 .8 3.7 7.6 11.7
Val379 10.3 21.9 15.2 21.6
Table 2
Linkage Disequilibrium between the Variants in Both Populations
Population His92/Thr198 (D/SE) Thr198/Val379 (D/SE) His92/Val379 (D/SE)
Atopic (German) 1.93 2.22a 3.04a
Asthmatic (British) 1.01 2.24a 6.41b
NOTE.—Linkage disequilibrium (D) was tested according to the method of Mittal (1976).
A t value calculated by D/SE 1 1.96 was considered positive. Substantial linkage disequilibrium
was seen for Thr198/Val379 and His92/Val379 in both populations.
a .P ! .05
b .P ! .01
kinetic studies are means of at least three independent
experiments.
Results
Polymorphisms
Screening for common polymorphisms in the PAFAH
gene was performed by SSCP analysis. Twelve PCR-
products covered the coding gene as well as the adjacent
splice sites. We could not detect the two “Japanese” loss-
of-function mutations Val279Phe and Gln281Arg in our
white populations; however, we picked up the variants
Arg92His (exon 4; position 275; GrA), Ile198Thr (exon
7; position 593; TrC) and Ala379Val (exon 11; position
1136; TrC). In addition, we localized a new, not-yet-
described conservative polymorphism in exon 2 that is
found at nucleotide position 211 relative to the “ATG”
start site, CrT. No polymorphisms were found in the
other exons tested.
Allele Frequencies
We determined the frequencies of the three alleles that
differed from the published genotype in all groups of
individuals, as shown in table 1. All variants were in
Hardy-Weinberg equilibrium with both populations
(German and British) calculated separately (data not
shown). The noncoding polymorphism in exon 2
occurred in !3% of the alleles and was not further
investigated.
Linkage Disequilibrium
Linkage disequilibrium between the three pairs of var-
iants was tested in the atopic and the asthmatic popu-
lation separately, as shown in table 2.
Association Studies
Atopic population.—The polymorphism Ile198Thr
showed association with atopic phenotypes, which was
highly significant for “total serum IgE” concentrations
( ) (table 3). The variant allele Thr198 was as-P = .0087
sociated with elevated total IgE concentrations. Regard-
ing the parameter estimate, the expected IgE level in the
presence of Thr198 was 2.4 times higher than the level
in wild-type individuals. The variant allele Val379 also
showed association with atopic phenotypes. The most
prominent significance was seen for “specific sensitiza-
tion” ( ; table 3).P = .0017
Asthmatic population.—The variant allele Thr198
showed significant association with the phenotype
“atopic asthma” ( ; table 4). The variant Val379P = .008
was significantly associated with “asthma” ( ;P = .003
table 4).
Functional Studies
These studies were performed using purified prepa-
rations of recombinant enzymes; an example is shown
in figure 1. We detected a KM of 7 mM for the wild-type
enzyme and a Vmax of 180 mmol/min # mg. The data
presented from the kinetic studies are mean values; av-
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Table 3
Association Studies of Common Variants in Plasmatic PAFAH with Atopy and Asthma—Atopic Population (German)
POLYMORPHISM
ATOPY SPECIFIC SENSITIZATION log (IgE)
Odds
Ratio 95% CI P Value
Odds
Ratio 95% CI P Value
Parameter
Estimate 95% CI P Value
His92 1.01 .54/1.88 .98 .98 .54/1.81 .97 2.04 .14/2.22 .66
Thr198 4.89 .79/30.1 .087 5.84 1.02/33.36 .047 .38 .098/.67 .0087
Val379 2.42 1.13/5.15 .022 3.25 1.56/6.78 .0017 .14 .033/.33 .11
NOTE.—Calculations for the phenotype “atopy” were performed with 199 affected and 61 control individuals, for the
phenotype specific sensitization with 189 affected and 71 control individuals and for the phenotype “ total serum IgE
(log IgE)” with 162 affected and 98 control individuals. Analysis followed the method of Zeger and Liang (1986) to
account for the correlation between sibs. The average IgE concentration in individuals bearing one of the polymorphisms
is calculated by 10 to the estimate. A P value of .009 was considered significant to account for multiple testing. Significant
associations (underlined) were seen for Thr198 (log IgE) and Val379 (specific sensitization).
Figure 1 Purification of pPAFAH by affinity chromatography
on Ni-NTA columns, shown for the wild-type enzyme. Lane 1, Mo-
lecular weight standard. Lane 2, Crude cell extract. Lane 3, Flow-
through. Lane 4, Wash. Lane 5, Purified enzyme.
erage standard errors in all experiments were 1–2 mM
for KM and 1/2 20 mmol/min # mg for Vmax.
The presence of the variant Val379 revealed a two-
times increased KM value (14 mM) (table 5). The variant
Thr198 showed a six-fold higher KM value (42 mM). This
effect was also seen in almost all combined mutated
enzyme forms bearing this polymorphism (table 5).
Vmax values were increased for the Val379 variant
(132%) (table 5). As expected from the literature, the
enzyme form bearing the polymorphism Val279Phe was
almost inactive and served as a control in activity tests.
Compared to the wild-type enzyme, lower substrate con-
centrations were necessary to inhibit the activities of the
recombinant enzyme Thr198, and markedly lower con-
centrations inhibited His92 and Val379 (fig. 2).
Discussion
Search for Polymorphisms and Association Studies
The aim of this study was to test for common poly-
morphisms in plasmatic PAFAH in white populations
and their potential association with asthmatic or atopic
phenotypes. This seemed reasonable regarding the in-
volvement of PAF in the attraction of eosinophils and
lymphocytes as the basis of IgE mediated responses
(Simon et al. 1994; Bartemes et al. 1999) and inflam-
mation and bronchoconstriction as the additional basis
of bronchial asthma (Miwa et al. 1988; Prescott et al.
1990). Furthermore, an association of two loss-of-func-
tion mutations of PAFAH with asthma severity has been
known (Stafforini et al. 1999a). However, these latter
two mutations are known only from Japanese individ-
uals (Satoh et al. 1999; Stafforini et al. 1999a) and also
had not been detected in a previous study screening a
British population (Bell et al. 1997).
All mutations found had already been known from
the literature, and all three of them had been used in an
association study to schizophrenia (Bell et al. 1997). The
polymorphism preceding the ATG start codon at posi-
tion 211 is described here for the first time. Possible
functional implications have not yet been tested.
With respect to atopy, association studies were applied
in a population of children and young adults aged 6–22
years to optimize the discrimination between affected
and nonaffected individuals. This age group represents
the most reliable test population, eliminating the pos-
sibility of sensitization being not yet or no longer de-
tectable. The atopic population was recruited through
an atopic index individual, without regard to clinical
symptoms.
To elucidate the influence of the PAFAH variants on
clinical asthma, the typing was repeated in a British pop-
ulation recruited through asthmatic index patients. In
our studies, the most prominent effect was seen for the
variant allele Thr198, which was associated with all phe-
notypes of “atopy” in the German population, whereby
the highest significance was found for total IgE levels
(the presence of the allele leading to 2.4 times higher IgE
levels; see table 3). The same accounts for the British
population, where Thr198 was found to be highly as-
sociated with the phenotype “atopic asthma” (table 4).
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Table 4
Association Studies of Common Variants in Plasmatic PAFAH with Atopy and
Asthma—Asthmatic Population (British)
POLYMORPHISM
ATOPIC ASTHMA ASTHMA
Odds
Ratio 95% CI P Value
Odds
Ratio 95% CI P Value
His92 1.15 .71/1.76 .64 1.11 .69/1.77 .68
Thr198 2.26 1.22/4.15 .008 1.49 .81/2.76 .20
Val379 1.67 1.02/2.71 .038 2.20 1.32/3.70 .003
NOTE.—Calculations for the phenotype “atopic asthma“ were performed with
150 affected and 150 control individuals, for the phenotype “asthma” with 181
affected and 119 control individuals. Analysis was performed with the SPSS pro-
gram (version 8) involving a Bonferroni correction (see Material and Methods). A
P value of .009 was considered significant to account for multiple testing. Significant
associations (underlined) were seen for Thr198 (atopic asthma) and Val379
(asthma).
Figure 2 Substrate inhibition assay with substrate concentra-
tions of 0.1–1 mM. Inhibition is shown in percent of the maximum
activity of the enzyme forms (= mean values of three independent
experiments). All polymorphic enzyme forms showed an increased
substrate inhibition compared to the wild type (wt). Dash-point-dash
line: wt; dash line: Arg92His (PAF 4); dotted line: Ile198Thr (PAF 7);
straight line: Ala379Val (PAF 11).
(Again, the presence of the allele leading to a 2.3-times-
higher odds ratio.) Likewise, the variant allele Val379
was associated with “atopy” in the German population
(table 3), showing the most prominent effects with “spe-
cific sensitization” and with “asthma” in the British pop-
ulation, including patients suffering from atopic and in-
trinsic asthma (table 4). The importance of the two
variants is stressed by the finding that the allele fre-
quencies are much higher in affected than in nonaffected
individuals in both populations (table 1). The polymor-
phism Arg92His does not seem to be associated with
atopy or asthma.
One should bear in mind that substantial linkage dis-
equilibrium between the variants has already been pub-
lished (Bell et al. 1997) and was shown in this study
also (table 2). That this was most prominent between
His92 and Val 379 but not between His92 and Thr198
was observed employing different statistical approaches
and might be due only to the low frequency of the
Thr198 allele. It might, however, also reflect a functional
link between His92 and Val379, with the presence of
both of them influencing the phenotype. This would be
equivalent to the findings on decreased Vmax for His92/
Val379 (PAF 4/11), as shown in table 5. A similar phe-
nomenon of potential functional links has been de-
scribed for IL4Ra, FceRIb and IL-4 variants (Adra et al.
1999; Suzuki et al. 1999; Shirakawa et al. 2000). We
suspected at least Thr198 and Val379 having an influ-
ence on enzyme characteristics. In order to prove our
assumptions, functional studies were applied.
Functional Studies
These studies were performed with different variant-
combinations of recombinant enzymes. Previously, it has
been shown that cloning and expression of plasmatic
PAFAH in E. coli does not alter the overall enzyme struc-
ture and activity (Tjoelker et al. 1995b).
Our kinetic experiments revealed a KM of 7 mM for
the wild-type enzyme and a Vmax of 180 mmol/min #
mg. These values are comparable to the ones found for
purified PAFAH from LDL, namely 12 mM and 170
mmol/min # mg (Tew et al. 1996). Slight alterations
might be due to the additional six histidine molecules
in our expression system or to the different purification
procedure.
Compared to the wild-type enzyme the molecular ac-
tivity (Vmax) was increased for Val379 (table 5), which
means that the turnover of substrate is increased. PAFAH
possessing Thr198 alone revealed no reduction in activ-
ity. This corresponds exactly to findings that were re-
cently made by Stafforini et al. (1999a). The combina-
tions of variants showed different effects concerning
Vmax (table 5), probably because of different influences
on enzyme conformation and the active site.
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Table 5
Kinetic Studies Performed with
Recombinant Enzymes of PAFAH
PROTEIN
PARAMETER
KM (mM) Vmax (%)
Wild type 7 100
His92 (PAF4) 9 108
Thr198 (PAF7) 42 100
Val379 (PAF11) 14 132
PAF 4/7 11 128
PAF 4/11 8 80
PAF 7/11 41 120
PAF 4/7/11 50 105
Phe279 Inactive Inactive
NOTE.—Kinetic studies were performed
with equal amounts of nine different re-
combinant proteins produced by PCR (Vec-
tor pQE [Qiagen]; expressed in E.coli
BL21DE3pLysS). Proteins were affinity pu-
rified. Enzymatic tests were performed by
means of the standard test (Stafforini et al.
1990), and the substrate acetyl-3H-PAF. KM
and Vmax were measured in three parallel
reactions with increasing substrate concen-
trations (1/10/50/100 mM). Mean values
were calculated. The protein Phe279 (loss
of function mutation) served as a control.
Data were fitted to the Michaelis-Menten
equation by nonlinear regression with the
program Enzfitter (Biosoft). Vmax values
are shown as percentage of the wild-type
level (wild type = 100%). Thr198 and
Val379 (alone and in combined forms)
showed highly increased KM, Val379 a
markedly increased Vmax.
The enzyme bearing the variant Thr198 showed a six-
fold higher KM value, Val379 revealed a two-fold higher
KM (table 5), which means a decreased substrate affinity.
This correlates with the association studies for Thr198
indicating total IgE levels being increased by a factor of
2.4 (positive parameter estimate of 0.38; table 3). In both
cases, PAF is degraded more slowly, and, consequently,
the signal transduction is prolonged. Finally, elevated
PAF concentrations might result in prolonged B cell sur-
vival (Toledano et al. 1999) and, consequently, higher
IgE levels or development of asthmatic symptoms. An
increase in PAF levels during acute asthmatic attacks has
been shown previously (Hsieh and Ng 1993). The strik-
ing KM effect was also seen in the combined mutant-
enzyme forms Thr198/Val379 and His92/Thr198/
Val379. An only slightly increased KM was seen for the
form His92/Thr198, which might be explained by con-
formational neutralization of the Thr198 influence (cis
effect). Presumably, individuals with two different alleles
(His92 and Thr198) will show an addition of influences
of the polymorphisms (trans effect) different from the
His92/Thr198 effect (cis effect). On the whole, His92,
not being associated with any phenotype tested, showed
wild-type enzyme characteristics regarding KM and
Vmax.
Substrate inhibition assays indicated alterations for
the variants His92, Thr198, and Val379. The enzyme
forms revealed an increased substrate inhibition com-
pared to the wild type, which would imply that lower
substrate concentrations are needed first to reach Vmax
and then again to inhibit the activity. The most striking
effects are seen for His92 and Val379. However, strictly
speaking, these results can be considered only from an
academic point of view, which means showing mere dif-
ferences in enzyme characteristics of the different vari-
ants in vivo. The range of substrate concentrations used
for this assay are far above physiological concentrations
of PAF measured in plasma (Stafforini et al. 1990). We
postulate conformational changes in the protein struc-
ture in case of any polymorphic status, and, at least
for the variants Thr198 and Val379, possible influences
on the active site leading to the altered enzyme
characteristics.
As indicated, we could not find an association of
His92 with IgE concentrations, although we saw func-
tional effects—for instance, in substrate inhibition as-
says. One should bear in mind that all associations
studied were performed in individuals with complex
genotypes regarding the PAFAH gene and that associ-
ation testing for any variant also covers adjacent variants
as long as they are in linkage disequilibrium. Arg92His
has been shown to be in such linkage disequilibrium with
Ile198Thr as well as Ala379Val (see above). Negative
association results might therefore reflect linkage rather
than missing functional effects, especially in the com-
bined enzyme forms (table 5).
The polymorphism Ile198Thr in human plasmatic PA-
FAH is located near tyrosine 205, which has been pro-
posed to be important for LDL binding (Stafforini et al.
1999b). The same accounts for the Trp115 and Leu116,
which are in the vicinity of Arg92His.
PAFAH circulates in a complex with LDL and HDL
in human plasma. These lipoproteins determine its cat-
alytic activity in vivo. The LDL-associated form of PA-
FAH is responsible for all of the PAF hydrolysis (Staf-
forini et al. 1999b). Therefore, it might well be that
especially Ile198Thr alters LDL binding and conse-
quently influences PAF degradation. Further studies on
the three-dimensional structure of plasmatic PAFAH
might help to test for this hypothesis. Ala379Val is sit-
uated in the vicinity of His351, one of the amino ac-
ids—along with Ser273 and Asp296—belonging to the
catalytic triad characteristic of phospholipases (Tjoelker
et al. 1995b), so the variant might influence enzymatic
activities.
In conclusion, Thr198 and Val379, the two common
variants of the plasmatic PAFAH, have been shown to
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be of functional importance, which parallels their as-
sociation with atopy and asthma. The basis of these
findings might be found in the influence of PAF on IgE
regulation as well as on inflammatory processes and
bronchoconstriction. This would also explain the pre-
viously described associations of these variants with
other inflammatory diseases. Finally, a suspected direct
role of human plasmatic PAFAH in the pathogenicity of
atopy and asthma in whites has been strengthened and
is not restricted to the presence of the two known loss-
of-function mutations.
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